Alzheimer's Research & Therapy

Submit a manuscript Register

Explore journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
		Review Lipidomics of Alzheimer's disease: current status Paul L Wood Alzheimer's Research & Therapy 2012, 4:5 (1 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Current applications of lipidomic technologies and the potential roles of lipid deficits and alterations in the pathophysiology of Alzheimer's disease (AD) are discussed by Wood.
		Review Progranulin axis and recent developments in frontotemporal lobar degeneration Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli, Rosa Rademakers Alzheimer's Research & Therapy 2012, 4:4 (23 January 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent data involving progranulin protein (PGRN) biology and frontotemporal lobar degeneration (FTLD), and the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration, is discussed by Nicholson and colleagues.
		Commentary Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design Benjamin Wolozin Alzheimer's Research & Therapy 2011, 4:3 (16 January 2012) Abstract \| Full text \| PDF
		Review Resting state functional MRI in Alzheimer's Disease Prashanthi Vemuri, David T Jones, Clifford R Jack Alzheimer's Research & Therapy 2011, 4:2 (10 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Vemuri and colleagues discuss the use of resting-state functional magnetic resonance imaging (fMRI) as an emerging Alzheimer's disease biomarker and consider future developments and open questions in the field.
		Review Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters, Wendy J Mack Alzheimer's Research & Therapy 2011, 4:1 (4 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Current studies fail to show a positive association between vascular risk factors and an increase in Alzheimer's disease (AD) pathology, as discussed in an evidence-based review by Chui and colleagues.
		Meeting report Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias Rachel F Lane, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:36 (20 December 2011) Abstract \| Full text \| PDF \| PubMed
		Review Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease Lori Frank, William R Lenderking, Kellee Howard, Marc Cantillon Alzheimer's Research & Therapy 2011, 3:35 (9 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The uses of, and issues associated with, patient-reported outcome measures in mild cognitive impairment and prodromal Alzheimer's disease are discussed by Frank and colleagues.
		Review Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development Agneta Nordberg Alzheimer's Research & Therapy 2011, 3:34 (2 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Nordberg reviews recent progress in molecular imaging and functional biomarkers, which can provide valuable information for early Alzheimer's disease (AD) detection, assessing disease progression, and the development of new therapeutics.
		Commentary Predicting Alzheimer's risk: why and how? Deborah E Barnes, Sei J Lee Alzheimer's Research & Therapy 2011, 3:33 (25 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In light of recent research, Barnes and Lee consider the current limitations and future directions in identifying individuals at increased risk of developing symptomatic Alzheimer's disease (AD).
		Research A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub, Alireza Atri Alzheimer's Research & Therapy 2011, 3:32 (11 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Uniform Data Set clinical researchers are provided with a new online interactive calculator that provides a normative score to help evaluate neuropsychological test performance in subjects with Alzheimer's disease.
		Review Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications Robert Laforce, Gil D Rabinovici Alzheimer's Research & Therapy 2011, 3:31 (10 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Potential clinical applications of amyloid positron emission tomography (PET) and its role in the differential diagnosis of a range of neurodegenerative conditions are reviewed by Laforce and Rabinovici.
		Commentary Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment Valory N Pavlik, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:30 (17 October 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Pavlik and Doody discuss findings in a recent study that older Alzheimer's disease (AD) patients and those with worse cognitive functioning had a better response to cholinesterase inhibitor treatment.
		Review Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney, Juha Yrjänheikki, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:28 (28 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Shineman and colleagues review the contribution of animal models to the understanding of biological mechanisms in Alzheimer's disease (AD) and how the translation of these models to human clinical trials might be improved.
		Commentary Defining and describing the pre-dementia stages of familial Alzheimer's disease Natalie S Ryan, Martin N Rossor Alzheimer's Research & Therapy 2011, 3:29 (27 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The need to establish a common framework for defining pre-dementia clinical stages of familial Alzheimer's disease (AD) is discussed by Ryan and Rosser, based on results from a recent study.
		Commentary Amyloid imaging in prodromal Alzheimer's disease Rik Ossenkoppele, Bart NM van Berckel, Niels D Prins Alzheimer's Research & Therapy 2011, 3:26 (19 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ossenkoppele and colleagues discuss a new study demonstrating that, due to a gradual increase in amyloid deposition, amyloid imaging can predict clinical progression to Alzheimer's disease (AD) in patients with mild cognitive impairment.
		Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
		Review Technical aspects of amyloid imaging for Alzheimer's disease Paul Edison, Rainer Hinz, David J Brooks Alzheimer's Research & Therapy 2011, 3:25 (31 August 2011) Abstract \| Full text \| PDF \| PubMed
		Review Globalization of Alzheimer's disease clinical trials Jeffrey Cummings, Robert Reynders, Kate Zhong Alzheimer's Research & Therapy 2011, 3:24 (17 August 2011) Abstract \| Full text \| PDF \| PubMed
		Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
		Review Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease Jake G Hoekstra, Kathleen S Montine, Jing Zhang, Thomas J Montine Alzheimer's Research & Therapy 2011, 3:21 (29 June 2011) Abstract \| Full text \| PDF \| PubMed
		Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
		Review The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease Robert Vassar, Patty C Kandalepas Alzheimer's Research & Therapy 2011, 3:20 (31 May 2011) Abstract \| Full text \| PDF \| PubMed
		Letter Should persons with autosomal dominant AD be included in clinical trials? Authors' response Kinga Szigeti, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:19 (23 May 2011) Abstract \| Full text \| PDF \| PubMed
		Letter Should persons with autosomal dominant AD be included in clinical trials? Joshua D Grill, John M Ringman Alzheimer's Research & Therapy 2011, 3:18 (23 May 2011) Abstract \| Full text \| PDF \| PubMed
		Editorial Right sizing funding for Alzheimer's disease Todd E Golde, Bruce T Lamb, Douglas Galasko Alzheimer's Research & Therapy 2011, 3:17 (6 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In their editorial, two of the journal’s Editors-in-Chief, and co-author Brian Lamb, call for additional funding to advance our understanding of this devastating disease and translate this into effective therapies.

	All
		Review Lipidomics of Alzheimer's disease: current status Paul L Wood Alzheimer's Research & Therapy 2012, 4:5 (1 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Current applications of lipidomic technologies and the potential roles of lipid deficits and alterations in the pathophysiology of Alzheimer's disease (AD) are discussed by Wood.
		Review Progranulin axis and recent developments in frontotemporal lobar degeneration Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli, Rosa Rademakers Alzheimer's Research & Therapy 2012, 4:4 (23 January 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent data involving progranulin protein (PGRN) biology and frontotemporal lobar degeneration (FTLD), and the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration, is discussed by Nicholson and colleagues.
		Commentary Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design Benjamin Wolozin Alzheimer's Research & Therapy 2011, 4:3 (16 January 2012) Abstract \| Full text \| PDF
		Review Resting state functional MRI in Alzheimer's Disease Prashanthi Vemuri, David T Jones, Clifford R Jack Alzheimer's Research & Therapy 2011, 4:2 (10 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Vemuri and colleagues discuss the use of resting-state functional magnetic resonance imaging (fMRI) as an emerging Alzheimer's disease biomarker and consider future developments and open questions in the field.
		Review Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters, Wendy J Mack Alzheimer's Research & Therapy 2011, 4:1 (4 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Current studies fail to show a positive association between vascular risk factors and an increase in Alzheimer's disease (AD) pathology, as discussed in an evidence-based review by Chui and colleagues.
		Meeting report Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias Rachel F Lane, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:36 (20 December 2011) Abstract \| Full text \| PDF \| PubMed
		Review Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease Lori Frank, William R Lenderking, Kellee Howard, Marc Cantillon Alzheimer's Research & Therapy 2011, 3:35 (9 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The uses of, and issues associated with, patient-reported outcome measures in mild cognitive impairment and prodromal Alzheimer's disease are discussed by Frank and colleagues.
		Review Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development Agneta Nordberg Alzheimer's Research & Therapy 2011, 3:34 (2 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Nordberg reviews recent progress in molecular imaging and functional biomarkers, which can provide valuable information for early Alzheimer's disease (AD) detection, assessing disease progression, and the development of new therapeutics.
		Commentary Predicting Alzheimer's risk: why and how? Deborah E Barnes, Sei J Lee Alzheimer's Research & Therapy 2011, 3:33 (25 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In light of recent research, Barnes and Lee consider the current limitations and future directions in identifying individuals at increased risk of developing symptomatic Alzheimer's disease (AD).
		Research A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub, Alireza Atri Alzheimer's Research & Therapy 2011, 3:32 (11 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Uniform Data Set clinical researchers are provided with a new online interactive calculator that provides a normative score to help evaluate neuropsychological test performance in subjects with Alzheimer's disease.
		Review Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications Robert Laforce, Gil D Rabinovici Alzheimer's Research & Therapy 2011, 3:31 (10 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Potential clinical applications of amyloid positron emission tomography (PET) and its role in the differential diagnosis of a range of neurodegenerative conditions are reviewed by Laforce and Rabinovici.
		Commentary Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment Valory N Pavlik, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:30 (17 October 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Pavlik and Doody discuss findings in a recent study that older Alzheimer's disease (AD) patients and those with worse cognitive functioning had a better response to cholinesterase inhibitor treatment.
		Review Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney, Juha Yrjänheikki, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:28 (28 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Shineman and colleagues review the contribution of animal models to the understanding of biological mechanisms in Alzheimer's disease (AD) and how the translation of these models to human clinical trials might be improved.
		Commentary Defining and describing the pre-dementia stages of familial Alzheimer's disease Natalie S Ryan, Martin N Rossor Alzheimer's Research & Therapy 2011, 3:29 (27 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The need to establish a common framework for defining pre-dementia clinical stages of familial Alzheimer's disease (AD) is discussed by Ryan and Rosser, based on results from a recent study.
		Commentary Amyloid imaging in prodromal Alzheimer's disease Rik Ossenkoppele, Bart NM van Berckel, Niels D Prins Alzheimer's Research & Therapy 2011, 3:26 (19 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ossenkoppele and colleagues discuss a new study demonstrating that, due to a gradual increase in amyloid deposition, amyloid imaging can predict clinical progression to Alzheimer's disease (AD) in patients with mild cognitive impairment.
		Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
		Review Technical aspects of amyloid imaging for Alzheimer's disease Paul Edison, Rainer Hinz, David J Brooks Alzheimer's Research & Therapy 2011, 3:25 (31 August 2011) Abstract \| Full text \| PDF \| PubMed
		Review Globalization of Alzheimer's disease clinical trials Jeffrey Cummings, Robert Reynders, Kate Zhong Alzheimer's Research & Therapy 2011, 3:24 (17 August 2011) Abstract \| Full text \| PDF \| PubMed
		Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
		Review Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease Jake G Hoekstra, Kathleen S Montine, Jing Zhang, Thomas J Montine Alzheimer's Research & Therapy 2011, 3:21 (29 June 2011) Abstract \| Full text \| PDF \| PubMed
		Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
		Review The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease Robert Vassar, Patty C Kandalepas Alzheimer's Research & Therapy 2011, 3:20 (31 May 2011) Abstract \| Full text \| PDF \| PubMed
		Letter Should persons with autosomal dominant AD be included in clinical trials? Authors' response Kinga Szigeti, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:19 (23 May 2011) Abstract \| Full text \| PDF \| PubMed
		Letter Should persons with autosomal dominant AD be included in clinical trials? Joshua D Grill, John M Ringman Alzheimer's Research & Therapy 2011, 3:18 (23 May 2011) Abstract \| Full text \| PDF \| PubMed
		Editorial Right sizing funding for Alzheimer's disease Todd E Golde, Bruce T Lamb, Douglas Galasko Alzheimer's Research & Therapy 2011, 3:17 (6 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In their editorial, two of the journal’s Editors-in-Chief, and co-author Brian Lamb, call for additional funding to advance our understanding of this devastating disease and translate this into effective therapies.